SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition

Wanchun Wang, Ding Chen and Kewei Zhu*

Abstract

Background: Doxorubicin is the preferred chemotherapeutic drug for osteosarcoma treatment of which clinical efficacy is limited because of its chemo-resistance and cardiac toxicity. It is necessary to develop the combination regimen with complementary molecular mechanisms to reduce the side effects and enhance sensitivity of Doxorubicin. EGCG is a polyphenol in green tea with antitumor bioactivity, which has been found that its combination with certain chemotherapeutic drugs could improve the antitumor efficiency.

Methods: In this study, MTT assay was used to detect the cell growth inhibition. The CD133+/CD44+ cells were isolated from U2OS and SaoS2 cell lines using magnetic-activated cell sorting and identified by flow cytometry analysis. qRT-PCR was used for determining the relative mRNA levels of key genes. Immunofluorescence was performed to evaluate the autophagy flux alterations. Self-renewal ability was accessed by sphere-forming assay. Tumorigenicity in nude mice was preformed to evaluate tumorigenicity in vivo.

Results: We found that EGCG targeting LncRNA SOX2OT variant 7 produced synergistic effects with Doxorubicin on osteosarcoma cell growth inhibition. On the one hand, EGCG could reduce the Doxorubicin-induced pro-survival autophagy through decreasing SOX2OT variant 7 to improve the growth inhibition of Doxorubicin. On the other hand, EGCG could partially inactivate Notch3/DLL3 signaling cascade targeting SOX2OT variant 7 to reduce the stemness then abated drug-resistance of osteosarcoma cells.

Conclusions: This study will help to reveal the molecular mechanisms of synergistic effects of EGCG and Doxorubicin on OS chemotherapy and improve the clinical efficacy of chemotherapy as well as provide a basis for developing antitumor drugs targeting osteosarcoma stem cells.

Keywords: Osteosarcoma, Doxorubicin, EGCG, SOX2OT, Autophagy, Cancer stem cells, Notch3

Background

Osteosarcoma is the most common histological form of primary bone tumors in children and adolescents which originates from the malignant transformation of mesenchymal cells with high mortality [1]. It often occurs during the differentiation of osteoid tissue and immature osteoblast. Doxorubicin (Dox) is one of the most commonly used chemotherapeutic drugs for osteosarcoma [2]. However, the intrinsic weakness of DOX severely limits its clinical efficacy: low-dose usage could not only reduce its effectiveness but also lead to drug resistance, while dose increment would cause severe cardiotoxicity [3]. Therefore, the overall survival rate of osteosarcoma patients is only 5 to 20% which is not satisfactory [4]. It is now generally recognized that the cancer stem cells (CSCs) could be a major cause of chemo-resistance and tumor recurrence [5]. Therefore, developing the combination regimen with potential complementary mechanisms, especially targeting CSCs, may be a promising avenue of drug toxicity reduction and efficacy improvement. Epigallocatechin gallate (EGCG) is the highest content of catechin in green tea with...
many physiological and pharmacological activities. It was found that EGCG could promote the sensitivity of traditional anticancer drugs [3, 6, 7] and reverse multidrug resistance [8]. Similarly, EGCG was reported to exert significant inhibitory effect on osteosarcoma cells including induce apoptosis, inhibit the proliferation and invasion of osteosarcoma cells [9–11].

Long non-coding RNAs have been reported to play important roles in tumor progression. Human SOX2 over lapping transcript (SOX2OT) gene can generate 8 lncRNA transcript variants (variant 1–8) which are functionally assumed to be correlated with cellular differentiation and carcinogenesis [12]. These variants show diverse expression profiles in different cell or tissue types [12]. It is worth mentioning that the SOX2OT harbors pluripotency regulator SOX2 and could positively regulate SOX2 expression [13, 14]. But so far, the expression and function of lncRNA SOX2OT variants in osteosarcoma is still unclear.

Our preliminary experiment surprised to find that the combination of EGCG and Dox could produce synergistic effect on osteosarcoma cell growth inhibition. Moreover, EGCG treatment resulted in LncRNA SOX2OT variant 7 downregulation in a concentration-dependent manner. Based on above description, this study investigated the underlying molecular mechanisms of the synergistic effect between Dox and EGCG targeting SOX2OT variant 7 and found that EGCG could decrease the Dox treatment-induced pro-survival autophagy partly through inhibiting SOX2OT variant 7 to improve the growth inhibition of Dox on osteosarcoma cells. On the other hand, EGCG could inactivate Notch3/DLL3 signaling targeting SOX2OT variant 7 to reduce the stemness of OS cells and then abated drug-resistance of osteosarcoma cells.

**Methods**

**Tumor cell culture and tumor sphere-forming culture**

The SaoS2 and U2OS osteosarcoma cell lines were purchased from the Cell Culture Center, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences (Shanghai, People’s Republic of China). The cells were maintained in DMEM supplemented with 10% FBS, 25 mM hydroxyethyl piperazine ethanesulfonic acid buffer, 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere of 5% carbon dioxide at 37 °C.

In order to form osteosarcoma spheres, 5 × 10^3 cells/well suspended OS cells were cultured in low-adhesive six-well plates in serum-free DMEM-F12 (1:1) medium supplemented with 20 ng/ml fibroblast growth factor (FGF; R&D systems), 20 ng/ml epidermal growth factor (EGF; R&D systems), B27 (1:50) (Invitrogen), N2 (1:100) (R&D systems), and 10 ng/ml LIF (Millipore) for 10 days (that is sphere-forming culture medium). In addition, fresh DMEM-F12 (1:1) medium, EGF, and bFGF were added every other day. A single-cell suspension derived from primary spheres was obtained for the secondary sphere formation with the same method.

**Patients and tissue samples**

10 pairs of OS tissue samples and their relative adjacent tissues were collected from the second Xiangya hospital from Dec, 2015 to March, 2016. Unfortunately, RNA degradation was found in 4 pairs of tissues which could not be used in subsequent experiments. Use of these samples for all experiments was approved by the Ethics Committee of the 2nd Xiangya Hospital of Central South University.

**Expression of SOX2OT variants in OS tissues and SOX2OT-V7 overexpressed lentivirus generation**

SOX2OT transcript variants were amplified separately using RT-PCR according to previous literature reports. U-87 MG cell line was used as positive control [13, 15, 16]. The SOX2OT V7 sequence was synthesized by BGI (Beijing, China). The synthetic V7 DNA fragment and lentiviral vector PGMLV-6395 were enzyme digested with BamH I/EcoRI, Ligation was performed to construct V7 overexpressed lentivirus recombinant plasmid. The following lentivirus package was performed by Auragene biotech (Changsha, China).

**MTT assay**

Cells were plated at a density of 5000 per well of a 96-well plate, 24 hafter plating, cells were treated as the indicated concentrations. 20 ml MTT with a concentration of 5 mg/ml was added to each well for an additional 4 hours. The blue MTT formazan precipitate was then dissolved in 150 μL of dimethyl sulfoxide per well with incubation for 10 min in a rotary platform at 37 °C. Cell proliferation inhibition ratio was calculated according to the absorbance at a wavelength of 570 nm (A value) in each well by ELISA analyzer (MK3, Themo, USA). Cell proliferation inhibition ratio (%) = (A value of control group–A value of treated group)/A value of control group× 100%.

**Analysis of in vitro drug interaction**

According to previous study [3], MTT assay was used to detect the absorbance at the wavelength of 570 nm as the OD value. The coefficient of drug interaction (CDI) was calculated as follows: CDI = AB/(A × B). According to the absorbance of each group, AB is the ratio of the combination groups to control group; A or B is the ratio of the single agent group to control group. Thus, CDI value< 1, = 1 or > 1 indicates that the drugs are synergistic, additive or antagonistic, respectively.

**Quantitative RT-PCR**

Total RNA was extracted from cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer's instructions, and then the RNA was reverse transcribed using the PrimeScript RT Master Mix Perfect Real Time kit (TaKaRa, Dalian, China) to obtain the cDNA. Using the cDNA as the template, real-time PCR assay was performed using the pairs of primers listed in Table 1. The 20 μL real-time PCR reaction included 0.5 μL of cDNA template, 0.25 μL of Forward/Reverse primers respectively, 10 μL of RNase-free dH₂O, and 8 μL of 2.5× Real Master Mix (SYBR Green I). The reaction conditions included a pre-denaturation step at 94 °C for 10 s, and 40 cycles of 94 °C for 15 s and 58 °C for 60 s. After the reaction, the data were subjected to statistical analysis.

**Western blot**

Cells were lysed in cell lysate, and then centrifuged at 12,000×g for 20 min at 4 °C. The supernatant was collected and denatured. Proteins were separated in 10% SDS-PAGE and blotted onto polyvinylidene difluoride membrane (PVDF). The PVDF membrane was treated with TBST containing 50 g/L skimmed milk at room temperature for 4 h, followed by incubation with the primary antibodies against the LC3B (1:3000, ab51520, Abcam), Atg5 (1:1000, ab108327, Abcam), Atg7 (1:100,000, ab524721,Abcam), Beclin1 (1 μg/ml, ab97959, Abcam) and anti-β-actin (1:1000, Cell signaling) respectively, at 37 °C for 1 h. Membranes were rinsed and incubated for 1 h with the correspondent peroxidase-conjugated secondary antibodies. Chemiluminescent detection was performed with the ECL kit (Pierce Chemical, Rockford, IL, USA). The amount of the protein of interest, expressed as arbitrary densitometric units, was normalized to the densitometric units of ß-actin.

**Purification of CD133+/CD44+ cancer stem cells**

CD133/CD44 immunomagnetic double screening were improved and performed according to the methods reported in previous literature [17]. A single-cell suspension of Saos-2 and U2OS cells was incubated with magnetic microbeads-conjugated with the mouse anti-human CD133 monoclonal antibody (Milteny Biotec, USA) for 30 min. After washing, the CD133+ cells were separated using the magnetic cell sorting system (autoMACS; Miltenyi Biotec, USA). The purified CD133+ cells were expanded for 14 days by culturing and then harvested as a single-cell suspension to be incubated with magnetic microbeads-conjugated mouse anti-human CD44 monoclonal antibody (Milteny Biotec, USA) for 30 min. After washing, the CD44+ cells were separated using the magnetic cell sorting system as described above. This two-step isolation enabled us to obtain sufficient number of CD133+/CD44+ CSCs for the following experiment.

To verify the purity of the isolated CD133+/CD44+ CSCs, cells were stained according to the supplied antibody protocols. Mouse anti-Human CD133/1

---

**Table 1 Primer sequence list**

| Gene     | Name       | Sequence               |
|----------|------------|------------------------|
| Atg5     | Sense      | TAAGTTTGGCTTTGTTT      |
|          | Antisense  | TTCCCTTCGATTATACCTCATC |
| Atg7     | Sense      | ATGCCTGCTCCATCGAAGACTTC |
|          | Antisense  | CATCATGAGAGATGACAGCA   |
| Becl1    | Sense      | TTGGGAATGAAATGAATAACAA |
|          | Antisense  | CCCCCAAGAAACAGTAACCGCC |
| SOX2OT-V7| Sense      | TCTGTTAGTTTGGAGAAAAG   |
|          | Antisense  | GCTTTGGACCCGCGGCT      |
| OCT-4    | Sense      | CCCTGGTGTTACCTTTCTTCT  |
|          | Antisense  | AGTGCTGGGACACTGGAAG    |
| CD44     | Sense      | GAGAGCAGCTCGAAGGTTAC   |
|          | Antisense  | GAAATGTGCTTGTCTGCTGTA  |
| Nanog    | Sense      | CTCTCCTCTCTCCCTCCTCAT  |
|          | Antisense  | TTGGCAGCTACCTCCTCTGC   |
| Notch1   | Sense      | CCGCCAGAGTGAGCGATGTA   |
|          | Antisense  | TGTCAGAGCTGAGCGTTCTGTA |
| Notch2   | Sense      | CACCAAAATGGAGACAGAC   |
|          | Antisense  | GAGGGCAAGGACACCAATA    |
| Notch3   | Sense      | TCTCAAGCTGGTCCGATCTCCAC |
|          | Antisense  | CCAAGATCTAAGAAGCTGAGCC |
| Jagged1  | Sense      | GACAGCCGGGTCAACCTGACAGTATA |
|          | Antisense  | GTCAAGGAAGCTGTAAGGGAGCA |
| Jagged2  | Sense      | TGCCGCCAGAGACTGTAAGAGGG |
|          | Antisense  | AATCACAGTAATAGGCCCGCAATCAGT |
| DLL1     | Sense      | AGGGGTGGAGAAAGCTGAGGAG |
|          | Antisense  | AACCTGCTCGTTGAAGCTCGT |
| DLL3     | Sense      | ACAGCCTGGCCTGCCACCTT   |
|          | Antisense  | CCGTCTAGGAGCCGAGCC   |
| DLL4     | Sense      | ACAGTGAAAAGCGAGGTGCTG |
|          | Antisense  | TGGAGCGGATGTTCAAGTGGAG |
| Hes1     | Sense      | CAGAAGATGATCAAAGCCTATT |
|          | Antisense  | TTCAGAGCATCCAAAATCAG   |
| Hey1     | Sense      | AGAGGAAATTGAGAGAGGG    |
|          | Antisense  | CAAACTCCGATAGCTCATAG  |
| β-actin  | Sense      | AGGGCCGCGACTGTCATACT  |
|          | Antisense  | GGCGCGACCACCATCTACCT  |

The sequence information of all primers used for qRT-PCR detection in this study was listed in the table.
and imported into Adobe Photoshop.

Images were captured immediately analyzed with a fluorescence microscope equipped with a filter system (V-2A excitation filter:380/420 nm, barrier filter:450 nm). Images were captured and imported into Adobe Photoshop.

**Self-renewal capacity assay**

To evaluate the colony-forming ability of different cells, self-renewal capacity assay was performed. We seeded OS cells or CSCs into 96-well plates at a density of $1 \times 10^3$ cells / well using sphere-forming culture medium with TGF-beta (20 ng/ml) and the formation of colonies was quantified at 14 days after inoculation. Colonies with over 50 cells were counted under an Olympus microscope.

**Autophagy detection**

In this study, autophagy levels were detected using immunofluorescence staining and MDC staining beside autophagy marker detection. Cells were cultured on cover glasses coated with 0.1% gelatin in PBS in 6-well tissue culture plates with DMEM. The cells were incubated overnight then washed with PBS, and fixed in 4% paraformaldehyde for 15 min. They were then permeabilized in 0.2% Triton X-100 for 10 min prior to blocking in 6% bovine serum albumin (BSA) for 30 min. For immunofluorescence staining, the cells were incubated overnight with anti-LC3B (1:200, 12741S, Cell Signaling, USA) at 4 °C, followed by incubation with goat anti-rabbit IgG (H + L)-Cy3 (1:200, SA012, Auragene) for 1 h at room temperature in dark. Nuclei were counterstained with DAPI (10 μg/ml, C0065, Solarbio, China). Finally, cells were analyzed using a confocal fluorescence microscope (BX50; Olympus, Japan) and the percentage of cells with LC3 puncta was calculated by taking advantage of Image-Pro Plus 6.0. When autophagic vacuoles were labeled with monodansylcadaverine (MDC), cells were incubated with 0.05 mM MDC in RPMI1640 at 37 °C for 10 min. After incubation, cells were washed three times with PBS and immediately analyzed with a fluorescence microscope equipped with a filter system (V-2A excitation filter:380/420 nm, barrier filter:450 nm). Images were captured and imported into Adobe Photoshop.

**Animal treatments**

Animal experiments were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals of the second Xiangya hospital of Central South University. The protocol was approved by the Committee on the Ethics of Animal Experiments of the second Xiangya hospital of Central South University. NOD/SCID mice at age of 3–5 weeks, male, were maintained in pathogen-free conditions at animal facility. The OSCs with or without SOX2OT V7 overexpression were resuspended in serum-free medium and mixed with Matrigel at the ratio of 1:1. NOD/SCID mice were randomly divided into 4 groups ($n=3$ per group). $1 \times 10^5$ indicated cells were inoculated subcutaneously into the inguinal folds of NOD/SCID mice. 7 days after inoculation, tumor formation was evaluated by palpation of injection sites, then the mice that developed palpable tumors were intraperitoneally injected EGCG (30 mg.kg-1) in combination with or without Notch-3 knockdown lentivirus (Lv-Notch3-) at the injection site every 3 days for 3 times. At the end of experiment (21 days), the mice were sacrificed under deep anesthesia with pentobarbital. The tumors were then dissected and captured.

**Statistical analysis**

Results from at least three independent experiments were expressed as mean ± SD. Statistical analysis of data from two groups was compared by two-tail t-test. Data from multiple groups wasperformed by one-way ANOVA, followed by Tukey post test. Statistical significance was determined as $P<0.05$.

**Results**

**Autophagy inhibition contributes to the synergistic interaction between EGCG and Doxorubicin to kill the osteosarcoma cells**

In order to determine whether EGCG could produce synergistic effects with Dox on osteosarcoma cell growth inhibition, MTT assays were applied and the coefficient of drug interaction (CDI) was calculated. The results showed either for U2OS or SaoS2 cell lines, when Dox was used in combination with EGCG, the growth inhibition was significantly up-regulated (Fig. 1a). As expected, according to the MTT assay and the coefficient of drug interaction (CDI, shown in Table 2), EGCG and DOX yielded synergistic interactions (CDI<1). As reported previously, autophagy contributed to the synergistic antitumor effects of EGCG and DOX [3], autophagy levels were detected in various ways. Firstly, immunofluorescence staining was performed to detect the LC3 translocation in U2OS cells. The results showed that in control group, LC3 was uniformly distributed in the cytoplasm, while LC3 expression occurred predominantly in punctuate dot-like structures when treated with Dox which was consistent with autophagy induction. Whereas the LC3 puncta decreased obviously in U2OS cells treated with EGCG combined with DOX (Fig. 1b). Secondly, the expression of autophagy markers were detected using qRT-PCR and western blot. It was found that, the relative mRNA levels of Atg5 and Beclin-1 were decreased significantly when OS cells were treated with Dox and EGCG together but there was no obvious expression alteration of Atg7 (Fig. 1c). The decrease in LC3II/I ratio and the simultaneous increase of...
Fig. 1 Autophagy inhibition contributes to synergistic interaction between EGCG and Doxorubicin to kill the osteosarcoma cells. **a** Combination of EGCG and DOX synergistically facilitate antitumor effects in U2OS and SaoS2 cell lines. Columns, percentage of inhibition ratio; bars, SE. Data was from a representative of 5 independent studies. *p < 0.05 vs. control group treated without EGCG but only 1 μM Dox, **p < 0.05 vs. control group treated without EGCG but only 2.5 μM Dox.

**b** Immunofluorescence analysis indicated that elevated LC3 fluorescent punctual signals were visualized in cells administrated with 2.5 mM DOX, while when EGCG was added, the LC3 fluorescence signal becomes weaker.

**c** Exposed to 2.5 μM Dox with or without 20 μg/ml EGCG for 24 h, the expression levels of Atg5, Atg7 and Beclin1 in OS cells were determined at the mRNA levels by qRT-PCR. Results shown are representative of three independent experiments and error bars indicate SE. *p < 0.05 vs. DOX single treated group.

**d** Cell lysates following DOX treatment with or without EGCG were subjected to western blotting. Protein ratios normalized to β-actin were used to quantify fold change.

**e** Cells were under different treatment, then MTT assay was performed to detect the growth inhibition. Data was from a representative of 5 independent studies. *p < 0.05 vs. DOX treated group without 3-MA, **p < 0.05 vs. combined treated group without Rapa.
autophagy substrate P62 suggested that autophagy levels were attenuated to some extent in the process of combining Dox with EGCG in both OS cell lines (Fig. 1d). In order to further define the synergistic growth inhibition between EGCG and DOX on OS cells was caused by autophagy mediation, cells were pre-treated with 3-MA or rapamycin (Rapa) respectively in different experimental groups. The MTT results showed that when pre-treated those cells with 3-MA, a representative autophagic antagonist, the DOX-induced proliferative inhibition effects was dramatically aggravated, while when pre-treated those cells with Rapa, a representative autophagic agonist, the synergistic growth inhibition effect of concurrent administration of EGCG and Dox was significantly decreased (Fig. 1e). The experimental results illustrated that EGCG-induced autophagy inhibition contributes to the synergistic interaction between EGCG and Doxorubicin to kill the osteosarcoma cells.

**Up-regulation of SOX2OT variant 7 in OS tumor tissues and cell lines**

Using qRT-PCR, we initially examined the expression pattern of newly identified human SOX2OT variants (transcripts 1/4/6/7/8) in 6 OS tumor tissue mixture, with specific primers for each variant [13]. A glioblastoma multiform cell line U-87 was utilized as a positive control to compare the expression pattern of the variants. As it is shown in Fig. 2a, no or very low expression was observed for SOX2OT transcripts 6 and 8. However, variant 1 showed a moderately high and variant 4 and 7 presented significantly high expression levels in OS tumor tissues. The expression pattern was different from that of U-87 which was used as a positive control.

The relative expression of the two most abundantly expressed SOX2OT variants (transcripts 1 and 7) were measured in OS tumor tissues and their responding adjacent tissues (n = 6) by qRT-PCR. The data was normalized to samples from adjacent tissues (A1) obtained from patient NO.1 (n = 6). The data revealed that SOX2OT variants 7 (V7) increased in 5/6 tumor tissues compared with their relative adjacent tissues (Fig. 2b). Besides, the relative mRNA levels of V7 were significantly in MG63, U2OS and SaoS2 cells when compared with primary osteoblast (Fig. 2c). These results indicated that V7 was overexpressed in osteosarcoma to some extent. It is noteworthy that the relative mRNA levels of V7 up-regulated obviously in OS cells treated with DOX but down-regulated in EGCG treated OS cells compared to control group. Meanwhile, the EGCG could decrease the V7 expression induced by DOX treatment significantly (Fig. 2d). These results suggested that V7 may be one of the important targets for EGCG to increase efficiency of DOX.

**EGCG inhibited DOX-induced autophagy by targeting SOX2OT V7 partially**

In order to explore the biological function of SOX2OT V7 in osteosarcoma, V7 gain-of-function OS cell models were established by V7 overexpressed lentivirus infection. qRT-PCR was performed to verify the efficiency of V7 overexpression. The results showed that in V7 gain-of-function cell models, mRNA level of SOX2OT-V7 enhanced significantly in both cell lines (Fig. 3a). At the same time, it was found that EGCG treatment could significantly reduce the endogenous expression level of V7 in both parental and V7 overexpressed OS cells. Therefore, V7 is one of the targets of EGCG in osteosarcoma cells. To investigate whether V7 is an autophagy regulator in OS cells, relative mRNA levels of autophagy associated genes Atg5, Atg7 and Beclin1 were detected using qRT-PCR. The results demonstrated that the relative mRNA levels of Atg5, Atg7 and Beclin1 were all up-regulated significantly in SOX2OT V7 overexpressed U2OS cells compared to control cells regardless of EGCG treatment (Fig. 3c). In order to explore whether the autophagy regulation of V7 is associated with the synergistic effects of EGCG and DOX, western blots, immunofluorescence staining and MDC staining were performed in SOX2OT V7 overexpressed OS cells under DOX treatment with or without EGCG. The results
showed that, when V7 was overexpressed in OS cells, the ratio of LC3II/I increased obviously and the autophagy substrate P62 decreased significantly which explained that SOX2OT V7 could induce autophagy in OS cells again. On the other hand, it was interesting that the inhibitory effect of EGCG on DOX-induced autophagy became faint in V7 overexpressed OS cells, the difference of the ratio of LC3II/I and the expression of P62 was not obvious between V7 overexpressed and control cells treated with DOX in combination with EGCG (Fig. 3d). Autophagy induction is associated with LC3, conjugated LC3 moves into autophagosomes and tightly binds to the autophagosome membrane. Thus, LC3 translocation is a reliable biomarker of autophagy [18]. Immunofluorescence staining was performed to detect the LC3 translocation. Meanwhile, MDC staining was another commonly used means of autophagy detection. The results showed that in control cells (Lv-Con), EGCG treatment could reduce the LC3 puncta and the MDC fluorescence signals obviously compared with DOX single treatment groups. While when V7 was overexpressed in OS cells, both the LC3 puncta and the MDC fluorescence signals enhanced obviously compared with the control group (Lv-Con). While, the difference of LC3 puncta and the MDC
fluorescence signals were not obvious between V7 overexpressed (Lv-SOX2OT-V7) and control cells (Lv-Con) treated with DOX in combination with EGCG (Fig. 3e). The above results basically prove that EGCG inhibited DOX-induced autophagy by targeting SOX2OT V7 partially.
EGCG reduced the expression of CSC markers of osteosarcoma stem cells

Cancer stem cells (CSCs) is a small subset of cancer cells characterized by self-renewal capability and pluripotent differentiation potential. Therefore, CSCs are believed to be of great importance in carcinogenesis, metastasis, drug-resistance and cancer recurrence. The existence of CSCs in osteosarcoma that are capable of forming suspended spherical, clonal colonies, preferentially express CSC key marker genes has been demonstrated [19]. EGCG could inhibit SOX2OT V7 which is closely related to pluripotency regulator SOX2 of CSCs, therefore, we speculated that EGCG would exert certain inhibitory effect on osteosarcoma stem cells (OSCs). CD133 is considered to be the most common CSC marker, and has been used repeatedly for the successful isolation of osteosarcoma stem cells [19]. A growing number of studies have found that using immunomagnetic double positive screening could obtain CSCs with higher purity and stemness [20, 21]. In this study, stem cell like cells were obtained from osteosarcoma cells by CD133+/CD44+ immunomagnetic beads double positive screening method and the isolated CD133+/CD44+ CSCs were identified by flow cytometry analysis. The results showed that after immunomagnetic double positive screening, the percentage of CD133+/CD44+ positive cells reached over 90% in U2OS (Fig. 4a) parental cells, which was significantly higher than that before screening. In order to further verify the relative stemness of cells after immunomagnetic beads screening, qRT-PCR was used to detect the relative mRNA levels of conventional OSC markers. The results showed the mRNA levels of Nanog, OCT4 and Sox2 were all upregulated significantly after CD133+ screening compared with their parental cells. It is worth mentioning that, after further CD44+ screening of CD133+ cells, further significant upregulation of Nanog, OCT4 and Sox2 was observed in CD133+/CD44+ cell compared with CD133+ cells (Fig. 4b). The results also illustrated to some extent that CD133+/CD44+ double positive screening was more effective than CD133+ single screening. On the other hand, mRNA level of SOX2OT V7 was also detected in immunomagnetic bead-screened cells and was found with similar alteration to those of OSC markers.(Fig. 4c). Subsequently, the screened CD133+/CD44+ cells were termed as OSCs. To determine whether EGCG could inhibit osteosarcoma stem cells in vitro, qRT-PCR and western blot were performed to detect the expression of OSC markers. The results showed the Nanog, OCT4, Sox2, c-Myc and ABCG2 were all upregulated significantly in OSCs compared with parental cells (Con), but their expression reduced obviously after EGCG addition compared with OSCs without EGCG treatment (Fig. 4d and e).

SOX2OT V7 is one of the important targets of EGCG inhibiting OSCs

After confirming that EGCG did inhibit OSCs, it was our next concern that the inhibition was partly targeting SOX2OT V7. OSCs screened from U2OS and SaoS2 were infected with V7 overexpressed lentivirus (Lv-V7) to generate gain-of-function OSC models of SOX2OT V7. qRT-PCR results showed that SOX2OT was successfully overexpressed in OSCs from both U2OS and SaoS2 (Fig. 5a). The sphere clone formation assay was performed to evaluate the self-renewal ability of OSCs. The results showed EGCG treatment could abate the tumor sphere formation ability of OSCs and V7 overexpression could enhance the spheroid formation ability in OSCs obviously not only in sphere number but also in spheroid size. While, when the V7 overexpressed OSCs were treated by EGCG with the same condition, the alteration of sphere formation ability was no longer obvious compared with V7 overexpressed OSCs treated without EGCG (Fig. 5b and C). Then, MTT assay was performed to study the inhibitory effect of EGCG and DOX, alone or in combination on OSC growth. It was demonstrated that EGCG could inhibit the growth of OSCs which seems slightly stronger than that of DOX. V7 over-expression in OSCs could reduce the growth inhibitory effect of both DOX and EGCG when they were single used. At the same time, the OSC growth inhibition effect of EGCG combined with DOX was also significantly decreased after overexpression of V7 in OSCs (Fig. 5d). These results suggested that EGCG inhibited the stemness of OSCs, and SOX2OT V7 was one of the important targets for the OSC inhibition of EGCG.

The OSC inhibitory effect of EGCG targeting SOX2OT V7 is partly achieved by restrain of Notch3 / DLL3 signaling

Notch signaling pathway plays an essential role in the development of cancer. Besides, Notch signaling pathway is also one of the classic signaling pathways of cancer stem cells. It was reported that EGCG could down-regulate the expression of Notch signaling genes and target genes [22–24]. To illustrate whether the OSC inhibitory effect of EGCG targeting SOX2OT V7 is partly achieved by mediating of Notch signaling, relative mRNA levels of target genes, receptors and ligands of Notch signaling were detected using qRT-PCR in V7 overexpressed OSCs with or without EGCG treatment. The results showed that the mRNA level of Notch target genes Hey1 and Hes1 enhanced significantly in OSCs compared with their parental cells. Besides, Hes1 and Hey1 expression further increased in V7 overexpressed OSCs compared with Lv-con OSCs. The results suggested V7 overexpression could further activated Notch signaling which has been active in OSCs. On the other hand, EGCG treatment
Fig. 4 (See legend on next page.)
could depress the mRNA levels of Hes1 and Hey1 in OSC control groups which indicated that EGCG inhibited the Notch signaling pathway in OSCs. However, the inhibitory effects of EGCG on Hes1 and Hey1 were not significant in V7 overexpressed OSCs which showed that overexpression of V7 was associated with a significant reduction in the inhibitory effect of EGCG on Notch signaling. To further understand the factors involved in this process, Notch receptors (Notch1/2/3) and ligands (Jagged1/2, Dll1/3/4) were investigated by qRT-PCR. The results showed only relative expression of Notch3 enhanced obviously compared with Lv-con group when V7 was overexpressed in OSCs. Meanwhile, EGCG treatment reduced Notch3 expression in Lv-con group cells which was almost abolished when V7 was overexpressed in OSCs. In terms of ligand, only DLL3 showed similar expression changes with Notch3 (Fig. 6a). Based on the above experimental results, we speculated preliminarily that Notch3/DLL3 signaling plays a role in OSC inhibitory effect of EGCG targeting SOX2OT.V7.

Then we used nude mouse tumorigenicity assay to further verify the above results (Table 3). It was demonstrated that, when being inoculated the same number of OSCs, V7 overexpressed OSCs induced tumors with larger volume compared with Lv-con group cells. In the course of tumorigenesis, EGCG was injected into nude mice inoculated with Lv-V7 OSCs which did not reduce the tumor size obviously. It is worth noting that the tumor size was much smaller when EGCG was injected into nude mice inoculated with Lv-V7 OSCs in combination of Notch3 knockdown lentivirus (Lv-Notch3-). This result was proved again that OSC inhibitory effect of EGCG targeting SOX2OT V7 was partly achieved by restrain of Notch3 to some extent (Fig. 6b and C).

**Discussion**

Osteosarcoma is the most common primary malignant bone tumor. One of the most active drugs for OS treatment is doxorubicin which is invariably included in OS chemotherapy protocols. Several studies have shown that high grade osteosarcoma patients may be inherently resistant to doxorubicin or become un-responsive to this drug during chemotherapy [25]. So, it is urgent to explore the combination regimen with complementary molecular mechanisms to reduce the side effects and enhance sensitivity of Doxorubicin. EGCG is a polyphenol in green tea with antitumor bioactivity which has been reported to show potential synergism with chemotherapy drugs in a few tumor types [6, 7]. Particularly, EGCG was found to have synergistic interaction with doxorubicin to kill the hepatoma Hep3B cells. Therefore, we hypothesized that EGCG and DOX also have synergistic inhibitory effects on osteosarcoma. Through the implementation of MTT experiment in which EGCG and DOX were used alone or in combination, the coefficient of drug interaction (CDI) was calculated and basically proved that they had synergistic effect on inhibiting the growth of osteosarcoma. The unknown molecular mechanism is another focus of this study.

DOX treatment could induce pro-survival autophagy in cells [26–28]. At the same time, EGCG promoted the growth inhibition effect of antitumor drugs through autophagy regulation via activation of pro-apoptosis or pro-survival autophagy in cancer cells [3, 29, 30]. Based on the synergistic effect of EGCG and DOX on osteosarcoma growth inhibition, in second part of this study, it was confirmed that EGCG inhibited DOX induced pro-survival autophagy which would be one of the important molecular mechanism of synergistic effect of EGCG and DOX on osteosarcoma. by detecting the expression of autophagy markers and immunofluorescence of LC3.

However, clarification of the targets of EGCG in this process was what attracts us to continue to explore. Our team was conducting exploratory functional studies of a series of LncRNAs in OS and fortunately, we found suspected targets of EGCG among them.

SOX2 overlapping transcript (SOX2OT) is a conserved lncRNA which encompasses sex determining region Y-box2 (SOX2) in the same strand [31]. SOX2OT have 8 transcript variants which expressions specifically in different human cancer cell lines [12]. In order to clarify differential expression of SOX2OT-spliced variants in OS tissue samples, 10 pairs of OS tissue samples and their relative adjacent tissues were collected from the second Xiangya hospital from Dec, 2015 to March, 2016. Unfortunately, RNA degradation was found in 4 pairs of tissues which could not be used in subsequent experiments. Since the expressions of variant 1, 4, 6, 7, 8 in
tumor tissues are relatively common, and glioma cell line U87 could be used as a positive control of variant expression, we used RT-PCR method to detect variants in OS tissues. According to the results, SOX2OT variants 1, 4, 7 were found expressed in OS tissues. However, whether variant 1, 4, 7 are all meaningful for osteosarcoma tumorigenesis is still unknown. Next, we confirmed the expression of variants 1, 4, 7 in the corresponding tumor tissues and their adjacent tissues again and found that only SOX2OT variant 7 showed obvious

Fig. 5 SOX2OT V7 is one of the important targets of EGCG inhibiting OSCs. OSCs screened from U2OS and SaoS2 were infected with V7 overexpression lentivirus (Lv-V7) to generate gain-of-function OSC models of SOX2OT V7. a qRT-PCR was performed to detect the mRNA level of SOX2OT V7 in V7 overexpressed OSCs. ** $p < 0.01$ vs. control lentivirus infected OSCs (Lv-con). The sphere clone formation assay was performed to evaluate the self-renewal ability of OSCs. b $1 \times 10^3$ OSCs were inoculated in 96-well plate and number of spheres per well was calculated on day 14. * $p < 0.05$ vs. control lentivirus infected OSCs (Lv-con). c Representative pictures of a tumor spheres were taken on the day 14, under 100 $\times$ magnification, the bar = 100 $\mu$m. d MTT assay was performed to study the inhibitory effect of EGCG and DOX, alone or in combination on OSC growth. * $p < 0.05$ vs Lv-con OSCs which were treated under the same treatment condition.
over-expression in tumor tissues compared with their adjacent tissues while neither V 4 nor V 1 showed obvious tendency of expression in tumor or adjacent tissues. Based on the above, we locked SOX2OT V7 as the main object of our study in OS although it was not enough to arrive at convincing and statistically significant conclusions because only 6 pairs of OS tissue samples were tested. Fortunately, we found that V7 seems to be one of the important targets in the study of EGCG inhibiting autophagy induced by DOX and then the follow-up experiments basically confirmed EGCG inhibited DOX-induced autophagy by targeting SOX2OT V7 partially.

Cancer stem cells are considered to be closely related to drug resistance of tumors because of enhanced expression of ABC transporter proteins and activated autophagy [32, 33]. In view of the inhibition of the SOX2OT V7 expression in osteosarcoma cells of EGCG and the close relationship between SOX2OT and CSC Fig. 6 The OSC inhibitory effect of EGCG targeting SOX2OT V7 is partly achieved by restrain of Notch3 / DLL3 signaling. To illustrate whether the OSC inhibitory effect of EGCG targeting SOX2OT V7 is partly achieved by mediating of Notch signaling, relative mRNA levels of target genes, receptors and ligands of Notch signaling were detected using qRT-PCR in V7 overexpressed OSCs with or without EGCG treatment. a. \( p < 0.05 \) vs. parental cells (Con), \( \alpha \) \( p < 0.01 \) vs. parental cells (Con), \( \beta \) \( p < 0.05 \) vs. control lentivirus infected OSCs (Lv-con).

b. Typical pictures of nude mice with tumorigenicity which were under different treatments. c. Typical pictures of stripped tumors derived from mice in different treatment groups.
pluripotent regulator SOX2, we put forward the hypothesis that EGCG could inhibit OSCs which would be another mechanism contributes to the Synergistic Interaction with Doxorubicin to osteosarcoma. EGCG could inhibit many kinds of cancer stem cells. But whether EGCG has an inhibitory effect on osteosarcoma stem cells has not been studied yet [34–36]. Through subsequent experiments, we have confirmed that EGCG can partially inhibit the self-renewal ability of OSC by targeting SOX2OT V7, and significantly enhance the inhibitory effect of DOX on OSC growth.

EGCG targeting lncRNA SOX2OT variant7 inhibits pro-survival autophagy induced by chemotherapeutic drugs (such as DOX), thereby enhancing the chemosensitivity of osteosarcoma cells; At the same time, EGCG targeting SOX2OT V7 decreases stemness of osteosarcoma stem cells (including drug resistance, tumorigenic ability, self-renewal ability, etc.). Notch signaling pathway is an evolutionarily conserved signaling pathway that controls the fate of cells and maintenance of stemness [37]. EGCG could inhibit Notch signaling pathway [22–24, 38], Especially, it was found that Notch signaling pathway inactivation can effectively reduce cisplatin induced osteosarcoma stem cells production and reduce the resistance of osteosarcoma cells [39], which suggested that Notch signaling pathway play a role in OS drug resistance and stemness. In our research, by detecting downstream target genes of Notch signaling (Hes1 and Hey1), it was proved that V7 overexpression; in the other hand, Notch ligands Jagged 1, DLL1 and DLL4 showed no obvious expression alterations in OSCs derived from both U2OS and SaoS2 with V7 overexpression, besides, the expressions of Jagged2 were even not significantly changed in any groups including in OSCs compared with parental group. According to the results of this study, in all ligands and receptors of the Notch signaling, only Notch 3 and DLL 3 met the expectations of this research. So, we conclude the OSC inhibitory effect of EGCG targeting SOX2OT V7 is partly achieved by restrain of Notch3 / DLL3 signaling.

Conclusions
EGCG targeting LncRNA SOX2OT variant7 via Notch3/ DLL3 plays a role in autophagy inhibition and stemness reduction which contributes to the synergistic interaction with Doxorubicin to osteosarcoma.

Table 3 Xenotransplantation of cells into NOD/SCID mice

| OSC groups | Inoculum size | Tumor incidence at D7 | Injection treatment From D7 to D21 | Tumor incidence at D21 | Tumor weight (g) |
|------------|---------------|-----------------------|-----------------------------------|------------------------|-----------------|
|            |               |                       |                                   |                        |                 |
| U2OS       |               |                       |                                   |                        |                 |
| 2003Lv-Con | 1 × 10^5      | 3/3                   | None                              | 3/3                    | 0.562 ± 0.046   |
| Lv-V7      | 1 × 10^5      | 3/3                   | EGCG                              | 3/3                    | 1.386 ± 0.027   |
|            |               |                       | EGCG+Lv-Notch3-                   | 3/3                    | 0.844 ± 0.036   |
| SaoS2      |               |                       |                                   |                        |                 |
| Lv-Con     | 1 × 10^5      | 3/3                   | None                              | 3/3                    | 0.499 ± 0.023   |
| Lv-V7      | 1 × 10^5      | 3/3                   | EGCG                              | 3/3                    | 1.456 ± 0.034   |
|            |               |                       | EGCG+Lv-Notch3-                   | 3/3                    | 0.860 ± 0.056   |

Wang et al. Journal of Experimental & Clinical Cancer Research (2018) 37:37

Funding
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. The relative E-mail address is 25325188@qq.com.

Acknowledgements
Thanks for the guidance and assistance given by Ms. Wei Wei in the compilation and submission of this article.

Abbreviations
CDI: The coefficient of drug interaction; CSCs: Cancer stem cells; Dox: Doxorubicin; EGCG: Epigallocatechin gallate; LncRNA: Long non-coding RNAs; OS: Osteosarcoma; OSCs: Osteosarcoma stem cells; SOX2OT: Human SOX2 Overlapping transcript.

Authors’ contributions
WW is one of thought designer of this study who gives a lot of experience and intellectual support in the process of the experiment, and writes the first draft of this article. KZ is the main designer of this research. DC and KZ worked together to complete the majority of the experiments of the study. KZ analyzed and arranged all the results of the experiments. All authors read and approved the final manuscript.
Ethics approval and consent to participate

Use of patient tissue samples for all experiments and the performance of animal experiments were approved by the Ethics Committee of the 2nd Xiangya Hospital of Central South University (2017 Ethical review No.3093).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 26 November 2017 Accepted: 23 January 2018
Published online: 23 February 2018

References

1. Ottaviani G, Robert RS, Huu WW, Palla S, Jaffe N. Sociooccupational and physical outcomes more than 20 years after the diagnosis of osteosarcoma in children and adolescents: limb salvage versus amputation. Cancer Biol Ther. 2013;19(20):3727–36.

2. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D. HMG81 promotes drug resistance in osteosarcoma. Cancer Res. 2012;72(1):230–8.

3. Chen L, Ye H, Zhang G, Yao WM, Chen XZ, Zhang FC, Liang G. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatooma Hep3B cells. PLoS One. 2014;9(1):e85771.

4. Zhang Z, Zhang Y, Li W, Zhang J. The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma. Int J Clin Exp Med. 2015;8(10):1830–2.

5. Kim HB, Lee SH, Um JH, Kim MJ, Hyun SK, Gong EJ, Oh WK, Kang CD, Kim SH. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int J Biol Sci. 2015;11(8):923–34.

6. Mayr C, Wagner A, Neureiter D, Pichler M, Jakab M, Illg R, Berner F, Kiesslich T. The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in bilayer tract cancer cells. BMC Complement Altern Med. 2015;15:194.

7. Wang P, Henning SM, Heber D, Vdsmga J. Sensitization to doxetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015;26(4):408–15.

8. Esmaeili MA. Combination of siRNA-directed gene silencing with epigallocatechin-3-gallate (EGCG) reverses drug resistance in human breast cancer cells. J Chem Biol. 2016;9(1):41–52.

9. Jiang L, Tao C, He A, He X. Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol. 2014;12:383.

10. Tang G, Zhang Z, Qian H, Chen J, Wang Y, Chen X, Chen B, Chen Y. (--)Epigallocatechin-3-gallate inhibits osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling pathway in human osteosarcoma cells. J Environ Pathol Toxicol Oncol. 2015;34(1):85–93.

11. Zhu X, Wang W. Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1. Tumour Biol. 2016;37(4):4373–82.

12. Saghaeian Jazi M, Samaei NM, Ghanei M, Shadmehr MB, Movsaj S. Identification of new SOX2OT transcript variants highly expressed in human cancer cell lines and down regulated in stem cell differentiation. Mol Biol Rep. 2016;43(2):65–72.

13. Askarian-Amini ME, Seyfoddin V, Smart CE, Wang J, Kim IE, Hansj H, Baguley BC, Finlay AJ, Leung EY. Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer. PLoS One. 2014;9(7):e102140.

14. Saghaeian Jazi M, Samaei NM, Ghanei M, Shadmehr MB, Movsaj S. Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer. Tumour Biol. 2016;37(8):10329–38.

15. Shih XM, Tseng F. Up-regulation of long non-coding RNA SOX2OT promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis. Int J Clin Exp Pathol. 2015;8(4):4008–14.

16. Ni M, Xiong M, Zhang X, Cai G, Chen H, Zeng Q, Yu Z. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells. Int J Nanomedicine. 2015;10:2537–54.

17. Ran X, Zhou P, Zhang K. Autophagy plays an important role in stemness mediated and the novel dual function of EG121 in both autophagy and stemness regulation of endometrial carcinoma JEC. Int J Oncol. 2017;51(2):644–56.

18. Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F, Yu P. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. Tumour Biol. 2015;36(12):9873–83.

19. Soner BC, Aktug H, Aclikogz F, Duzacag F, Gunen U, Ayla S, Cali C, Oldem G. Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol. Int J Mol Med. 2014;34(5):1249–56.

20. Xiao W, Gao Z, Duan Y, Yuan W, Ke Y. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):41.

21. Gu LT, Yang J, Su SZ, Liu WW, Shi ZZ, Wang QR. Green tea Polyphenols protects Cochlear hair cells from Ototoxicity by inhibiting Notch Signalling. Neurochem Res. 2015;40(6):1211–9.

22. Jin H, Gong W, Zhang C, Wang S. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. OncoTargets Ther. 2013;6:145–53.

23. Lee SH, Nam HK, Kang HJ, Kwon HW, Lim YC. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer (Oxford, England : 1990). 2013;49(15):3210–8.

24. Hattinger CM, Fanelli M, Tavanti E, Vella S, Rignani C, Picci P, Serra M. Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight? Future Oncol. 2017;13(8):673–7.

25. Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K, Li L. MiR-26 enhances chemoresistance and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis. 2017;8(1):e2540.

26. Sun R, Shen S, Zhang YJ, Xu CF, Gao ZT, Wen LP, Wang J. Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. Biomaterials. 2016;103:44–55.

27. Wang X, Wang XL, Chen HL, Wu D, Chen JX, Wang XX, Li RL, He JH, Mo L, Cen X, et al. Gnelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol. 2014;88(3):334–50.

28. Hu F, Wei F, Wang Y, Wu B, Fang Y, Xiong B. EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells. J Pharmcol Sci. 2015;128(1):27–34.

29. Yuan CH, Hong CT, Lee CF, Chiang NN, Tsai FJ, Lu CC, Chiang JH, Hsu YM, Yang JS, Chen FA. Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer cell CAR apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling. Environ Toxicol. 2017;32(3):845–55.

30. Fantjes J, Ragge NK, Lynch SA, McGill NJ, Collin JR, Howard-Peebles PN, Hayward C, Vivian AJ, Williamson K, van Heyningen V, et al. Mutations in SOX2 cause anophthalmia. Nat Genet. 2003;33(4):461–3.

31. De Angelis ML, De Maria R, Baiocchi M. How to assess drug resistance in breast cancer stem cells. Methods Mol Biol. 2018;1692:107–15.

32. Pagotto A, Pilottto G, Mazzoldi EL, Nicelli MO, Frezzi S, Pasto A, Amadori A. Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells. Cell Death Dis. 2017;8(7):e2943.

33. Kumazoe M, Takai M, Hiroi S, Takeuchi C, Yamada S, Saito Y, Arakawa Y, Imura S. Epigallocatechin gallate hinders ABCG2/CD133+ and ABCG2/CD133+ prostate cancer stem cells by flavopiridol. Int J Mol Med. 2014;34(5):1249–56.

34. WabatGU, Shinohara M, Morine Y, Ikemoto T, Ishikawa D, Iwashishi Y, Yamada S, Saito Y, Arakawa Y, Imura S. Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation. Gastroenterol Hepatol. 2016;31(1):256–64.

35. Zhu J, Jiang Y, Yang X, Wang S, Xie C, Li X, Li Y, Chen Y, Wang X, Meng Y, et al. Wnt/beta-catenin pathway mediates (--)Epigallocatechin-3-gallate (EGCG) inhibition of lung cancer stem cells. Biochem Biophys Res Commun. 2017;482(1):15–21.

36. Zhou X, Tseng L, Wang M. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer. Tumour Biol. 2016;37(5):6979–85.
38. Xie H, Sun J, Chen Y, Zong M, Li S, Wang Y. EGCG attenuates uric acid-induced inflammatory and oxidative stress responses by medicating the NOTCH pathway. Oxidative Med Cell Longev. 2015;2015:214836.

39. Yu L, Fan Z, Fang S, Yang J, Gao T, Simoes BM, Eyre R, Guo W, Clarke RB. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling. Oncotarget. 2016;7(22):33055–68.